1. Home
  2. TSAT vs ALLO Comparison

TSAT vs ALLO Comparison

Compare TSAT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSAT
  • ALLO
  • Stock Information
  • Founded
  • TSAT 1969
  • ALLO 2017
  • Country
  • TSAT Canada
  • ALLO United States
  • Employees
  • TSAT N/A
  • ALLO N/A
  • Industry
  • TSAT Metal Fabrications
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TSAT Industrials
  • ALLO Health Care
  • Exchange
  • TSAT Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • TSAT 233.1M
  • ALLO 277.8M
  • IPO Year
  • TSAT 1996
  • ALLO 2018
  • Fundamental
  • Price
  • TSAT $23.41
  • ALLO $1.30
  • Analyst Decision
  • TSAT
  • ALLO Strong Buy
  • Analyst Count
  • TSAT 0
  • ALLO 9
  • Target Price
  • TSAT N/A
  • ALLO $8.44
  • AVG Volume (30 Days)
  • TSAT 165.1K
  • ALLO 3.2M
  • Earning Date
  • TSAT 08-13-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • TSAT N/A
  • ALLO N/A
  • EPS Growth
  • TSAT N/A
  • ALLO N/A
  • EPS
  • TSAT N/A
  • ALLO N/A
  • Revenue
  • TSAT $372,642,710.00
  • ALLO N/A
  • Revenue This Year
  • TSAT N/A
  • ALLO N/A
  • Revenue Next Year
  • TSAT N/A
  • ALLO $199.63
  • P/E Ratio
  • TSAT N/A
  • ALLO N/A
  • Revenue Growth
  • TSAT N/A
  • ALLO N/A
  • 52 Week Low
  • TSAT $7.21
  • ALLO $0.86
  • 52 Week High
  • TSAT $27.45
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • TSAT 65.95
  • ALLO 46.23
  • Support Level
  • TSAT $25.26
  • ALLO $1.13
  • Resistance Level
  • TSAT $27.45
  • ALLO $1.26
  • Average True Range (ATR)
  • TSAT 1.70
  • ALLO 0.08
  • MACD
  • TSAT 0.01
  • ALLO -0.00
  • Stochastic Oscillator
  • TSAT 66.48
  • ALLO 43.18

About TSAT Telesat Corporation and Class B Variable Voting Shares

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: